In late January, CARsgen Therapeutics, a biopharmaceutical company with operations in China and the U.S., started moving employees into a biomanufacturing facility in Durham, N.C., the company’s first such operations in North America.
/PRNewswire/ CARsgen Therapeutics, a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid.